Please login to the form below
baricitinib
This page shows the latest baricitinib news and features for those working in and with pharma, biotech and healthcare.
Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval
Last week, Eli Lilly and Incyte’s repurposed arthritis treatment baricitinib also scored an EUA in combination with Gilead’s remdesivir for the treatment of hospitalised COVID-19 patients.
Latest news
-
Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval
Patients treated with the baricitinib/remdesivir regimen were also more likely to have a better clinical status at day 15 compared to remdesivir monotherapy. ... 35%. Baricitinib is already marketed by Lilly as Olumiant, for the treatment of adults with
-
Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures
inhibitor Olumiant (baricitinib) for the novel coronavirus.
-
Lilly seeks US emergency approval after posting new data for COVID-19 antibodies
In addition to its studies of the COVID-19 targeting antibodies, Lilly is also undertaking clinical development of its JAK inhibitor Olumiant (baricitinib) in combination with Gilead’s remdesivir in patients
-
Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19
The ACTT-2 trial, which was sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), evaluated a 4mg dose of Olumiant (baricitinib) given alongside remdesivir versus remdesivir alone ... This data allows us to better understand
-
AbbVie, Amgen and Takeda team up for joint COVID-19 trial
This includes remdesivir, and Gilead is planning combination studies of the antiviral drug when taken alongside Eli Lilly’s JAK inhibitor Olumiant (baricitinib) and Actemra.
More from news
Approximately 10 fully matching, plus 38 partially matching documents found.
Latest Intelligence
-
NICE – but not enough
A great illustration of why this is unfortunately a myth can be seen in Figure 1, which charts the formulary adoption of Olumiant (baricitinib) – Lilly’s once-daily pill for moderate
-
AI: the smart money is on the smart thinking
Take, for example, the case of baricitinib, originally an Eli Lilly rheumatoid arthritis drug, now repurposed as a promising treatment for COVID-19.
-
Drug launches to watch in 2019
Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
-
Live webinar: Navigating new frontiers: Ways to find space in the future RA market
Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Account Director
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
-
Medical Editor
-
Competitive
- EU secures 405 million doses of CureVac’s COVID-19 vaccine
- Pfizer, Mylan move ahead with generics merger and spin-out
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year
- FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions
- Send Us a Message
- Laurence Bannister joins Lucid Group as its new Chief Commercial Officer
- AZ’s COVID-19 vaccine demonstrates efficacy rate of up to 90%
- UK could approve Pfizer’s COVID-19 vaccine this week
- Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval
- Power to the patient: digital innovation supporting patients with chronic diseases
- New from the PhRMA: Diversity in clinical trials principles summarised
PMHub
Kendle Healthcare
Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...
Latest intelligence
- New from the PhRMA: Diversity in clinical trials principles summarised
- In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
- New from the FDA: Diversity in clinical trials guidance summarised
- In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
- 5 steps to effective clinical trial branding
- When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...
Quick links
Infographics
